While platform players are going super-wide in their offering, some legal AI startups are going the other way and drilling ...

Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. See ...

A recent White House executive order could make it harder for millions of Americans to access their lifesaving medications.

FDA’s public guidance continues to warn that, “under most circumstances,” importing drugs for personal use is unlawful, ...

CEO of the National Infusion Center Association argues against a drug price control policy known as “most favored nation.” ...

Worries about further hiccups in the potential trade deal and consequent higher tariffs between India and the United States ...

India wants the U.S. to remove all tariffs—both MFN and country-specific—on high and medium-labour-intensive goods. These ...

The MFN EO is designed to halt what the administration calls “global freeloading” — where other developed countries benefit from U.S.-funded drug innovation at significantly lower costs.

Yellow Corp. and its largest shareholder urged a federal appeals court panel to overturn a bankruptcy court ruling on what ...

President Donald Trump issued an executive order reviving his controversial “Most Favored Nation” (MFN) drug pricing ...